Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Sensei Biotherapeutics Inc (NASDAQ:SNSE)
|Dividend Rate (ttm)||0.0000|
|Trading Day||Sep 17|
|Day's Range||9.96 - 10.89|
|52 Week Range||6.74 - 26.5|
Sensei Biotherapeutics Inc dividends
Sensei Biotherapeutics Inc has a market cap or net worth of $304.66 million. The enterprise value is $0.
Sensei Biotherapeutics Inc has 30.59 million shares outstanding.
The trailing PE ratio is 0.0000 and the forward PE ratio is 0.0000. Sensei Biotherapeutics Inc's PEG ratio is 0.0000.
Stock Price Statistics
The stock price has decreased by -0.4138%. The beta is 0.0000, so Sensei Biotherapeutics Inc's price volatility has been lower than the market average.
In the last 12 months, Sensei Biotherapeutics Inc had revenue of $0 and earned $0 in profits. Earnings per share was $.
Sensei Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company has developed a proprietary bacteriophage-based platform, ImmunoPhage™, that enables the rapid generation of immune activating therapeutic agents that fully engage the immune system.
Using the ImmunoPhage™ platform, Sensei is developing a library of ImmunoPhage, called Phortress™, to target multiple tumor-associated antigens to create a personalized yet off-the-shelf cocktail approach for treating cancer patients. The platform enables efficient, scalable and cost-effective manufacturing to support all of Sensei’s clinical programs.
The company’s most advanced immunotherapy, SNS-301, a first-in-class ImmunoPhage™ targeting the tumor antigen Aspartyl beta Hydroxylase (ASPH), is currently in a Phase 1/2 clinical trial in patients with advanced Squamous Cell Carcinoma of the Head and Neck. Earlier stage programs include SNS-401, a ImmunoPhage™ cocktail for the treatment of Merkel Cell Carcinoma, and SNS-VISTA, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA)..